Keflex®
Cephalexin · oral capsule
Antibiotic
Approved uses
Skin and skin structure infections caused by susceptible bacteria
250 mg every 6 hours, or 500 mg every 12 hours, in adults and patients aged 15 and over
The row an optometrist reaches for; the dose is the same whether the skin in question is on an arm or a lid
Respiratory tract infection, otitis media, bone infection and genitourinary tract infection
250 mg every 6 hours or 500 mg every 12 hours in adults; 75 to 100 mg/kg daily in divided doses for otitis media in children over 1 year
Contraindications
Patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs.
Capsules 250 mg, 333 mg, 500 mg, 750 mg; bottles of 20, 100, 500, 1000; 750 mg also bottles of 50; unit-dose packs (not 750 mg)
Cephalosporin antibacterial drug; bactericidal, acting by inhibition of bacterial cell-wall synthesis.
Warnings & Precautions
- Hypersensitivity reactions: Rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported; before therapy, ask about prior hypersensitivity to cephalexin, cephalosporins, penicillins, or other drugs; cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy; if an allergic reaction occurs, discontinue the drug and institute appropriate treatment.
- Clostridium difficile-associated diarrhea: CDAD has been reported with nearly all antibacterial agents, including cephalexin, and may range from mild diarrhea to fatal colitis; consider it in all patients with diarrhea after antibiotic use; a careful medical history is necessary since CDAD has been reported over two months after administration of antibacterial agents; if CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
- Direct Coombs' test seroconversion: Positive direct Coombs' tests have been reported with cephalosporins including cephalexin, and acute intravascular hemolysis induced by cephalexin has been reported; if anemia develops during or after therapy, perform a diagnostic work-up for drug-induced hemolytic anemia, discontinue cephalexin and institute appropriate therapy.
- Seizure potential: Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced; if seizures occur, discontinue cephalexin.
- Prolonged prothrombin time: Cephalosporins may be associated with prolonged prothrombin time; those at risk include patients with renal or hepatic impairment, poor nutritional state, a protracted course of antibacterial therapy, or anticoagulant therapy; monitor prothrombin time in patients at risk.
- Development of drug-resistant bacteria: Prescribing cephalexin without a proven or strongly suspected bacterial infection is unlikely to help and increases the risk of drug-resistant bacteria; prolonged use may result in overgrowth of nonsusceptible organisms, and superinfection calls for appropriate measures.
Common Side Effects
The most common adverse reactions are diarrhea, nausea, vomiting, dyspepsia and abdominal pain.
Pregnancy: Published epidemiologic studies and pharmacovigilance case reports over several decades of cephalosporin use, including cephalexin, have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; oral doses in mice and rats of 0.6 and 1.2 times the MRHD during organogenesis showed no fetal harm.
Lactation: Cephalexin is present in human milk, with a relative infant dose under 1% of the maternal weight-adjusted dose; there are no data on effects on the breastfed child or on milk production; weigh the benefits of breastfeeding against the mother's clinical need and any potential adverse effects on the child.
Safety and effectiveness established in clinical trials for the labeled dosages in pediatric patients over 1 year of age.